Hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: a randomized-controlled study

被引:6
|
作者
Yu, Pengfei [1 ]
Huang, Xingmao [1 ]
Huang, Ling [1 ]
Dai, Gaiguo [1 ]
Xu, Qi [2 ]
Fang, Jingquan [1 ]
Ye, Zeyao [1 ]
Chai, Tengjiao [1 ]
Du, Yian [1 ]
机构
[1] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Dept Gastr Surg, Hangzhou 310022, Zhejiang, Peoples R China
[2] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Dept Med Oncol, Hangzhou 310022, Zhejiang, Peoples R China
关键词
Gastric cancer; Chemotherapy; Hyperthermic intraperitoneal chemotherapy (HIPEC); Peritoneal metastasis; Prognosis; CYTOREDUCTIVE SURGERY; PERITONEAL PERFUSION; OPEN-LABEL; CLASSIFICATION; COMPLICATIONS; CAPECITABINE; CISPLATIN; EFFICACY; TRIAL;
D O I
10.1007/s00432-023-05019-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Currently, there is a lack of an effective strategy for the prevention of peritoneal metastasis (PM) from locally advanced gastric cancer (AGC). This randomized-controlled study aimed to evaluate the outcome of D2 radical resection with hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally AGC patients. Methods All enrolled patients were randomly assigned to receive HIPEC plus systemic chemotherapy (HIPEC group) or systemic chemotherapy alone (non-HIPEC group) after radical gastrectomy. HIPEC was performed intraperitoneally with cisplatin (40 mg/m(2)) within 72 h after surgery, while systemic chemotherapy based on the SOX regimen (S-1 combined with oxaliplatin) was administered 4-6 weeks after radical surgery. Patterns of recurrence, adverse events, 3-year disease-free survival (DFS), and overall survival (OS) were analyzed. Results A total of 134 patients were enrolled in the present study. The 3-year DFS rate was 73.8% in the HIPEC group, which was significantly higher than that in the non-HIPEC group (61.2%, P = 0.031). The 3-year OS rate was 73.9% in the HIPEC group and 77.6% in the non-HIPEC group, with no significant difference (P = 0.737). PM was the most common distant metastasis in both groups. The occurrence rate of PM in the HIPEC group was statistically lower than that in the non-HIPEC group (20.9% vs. 40.3%, P = 0.015). Grade 3 or 4 adverse events occurred in 19 (14.2%) patients, and there was no significant difference between the two groups. Conclusion Radical surgery followed by HIPEC combined with systemic chemotherapy is a safe and feasible strategy for locally AGC patients and could effectively improve DFS and reduce the occurrence of PM. However, more prospective randomized studies with a large sample size are warranted.
引用
收藏
页码:11491 / 11498
页数:8
相关论文
共 50 条
  • [1] Hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: a randomized-controlled study
    Pengfei Yu
    Xingmao Huang
    Ling Huang
    Gaiguo Dai
    Qi Xu
    Jingquan Fang
    Zeyao Ye
    Tengjiao Chai
    Yian Du
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 11491 - 11498
  • [2] Adjuvant combined systemic chemotherapy and intraperitoneal chemotherapy for locally advanced gastric cancer
    Xue, Sheng-Liu
    Su, Hua-Fang
    Hu, Xiao-Qu
    Deng, Xia
    Hu, Mei-Long
    Xie, Cong-Ying
    ONCOLOGY LETTERS, 2012, 4 (06) : 1309 - 1314
  • [3] Efficacy of Adjuvant Systemic Chemotherapy Combined with Radical Surgery and Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer Treatment
    Reutovich, M. Yu
    Krasko, O., V
    Sukonko, O. G.
    INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2020, 11 (03) : 337 - 343
  • [4] A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection
    Zhu, Wei-guo
    Xua, Da-fu
    Pu, Jun
    Zong, Cheng-dong
    Li, Tao
    Tao, Guang-zhou
    Ji, Fu-zhi
    Zhou, Xi-lei
    Han, Ji-hua
    Wang, Cheng-shi
    Yu, Chang-hua
    Yi, Jiang-guo
    Su, Xi-long
    Ding, Jin-xia
    RADIOTHERAPY AND ONCOLOGY, 2012, 104 (03) : 361 - 366
  • [5] Efficacy analysis of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer: a retrospective study
    Gong, Zhijie
    Zhou, Liping
    He, Yinghao
    Zhou, Jun
    Deng, Yanjie
    Huang, Zudong
    Wang, Weiwei
    Yang, Qiangbang
    Pan, Jian
    Li, Yingze
    Yuan, Xiaolu
    Ma, Minghui
    FRONTIERS IN ONCOLOGY, 2025, 14
  • [6] Perioperative intraperitoneal plus systemic chemotherapy and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for gastric cancer: phase Ib/II single-arm prospective study
    Cho, Minah
    Kim, Hyo Song
    Jung, Minkyu
    Hyung, Woo Jin
    JOURNAL OF GASTROINTESTINAL SURGERY, 2024, 28 (07) : 1095 - 1103
  • [7] Efficacy of Adjuvant Systemic Chemotherapy Combined with Radical Surgery and Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer Treatment
    M. Yu. Reutovich
    O. V. Krasko
    O. G. Sukonko
    Indian Journal of Surgical Oncology, 2020, 11 : 337 - 343
  • [8] Comparison of the Efficacy of D2 Gastrectomy Plus Liver Radiofrequency Combined With Chemotherapy Versus Chemotherapy Alone in the Treatment of Advanced Gastric Cancer With Unresectable Synchronous Liver Metastases: A Multicenter Randomized Controlled Trial Protocol
    Wang, Weidong
    Gao, Ruiqi
    Yu, Pengfei
    Mo, Zhenchang
    Dong, Danhong
    Yang, Xisheng
    Li, Xiaohua
    Ji, Gang
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] Hyperthermic intraperitoneal chemotherapy plus SOX chemotherapy versus SOX chemotherapy alone in patients with gastric cancer and peritoneal metastasis: a phase II randomized clinical trial
    Luo, Lijie
    Zhang, Zijing
    Zeng, Haiping
    Xu, Yuting
    Peng, Yaohui
    Huang, Haipeng
    Lin, Zeyu
    Xiong, Wenjun
    Wang, Wei
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2025, 16 (01) : 17 - 26
  • [10] Adjuvant Chemotherapy Plus Radiotherapy versus Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy
    Ernandez, John
    Kaul, Sumedh
    Fleishman, Aaron
    Korets, Ruslan
    Chang, Peter
    Wagner, Andrew
    Kim, Simon
    Bellmunt, Joaquim
    Kaplan, Irving
    Olumi, Aria F.
    Gershman, Boris
    BLADDER CANCER, 2022, 8 (04) : 405 - 417